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Diabetes mellitus (DM) is a global epidemic, and diabetic foot ulcer (DFU) is one of its most serious and 
costly complications. DFUs result from a complex interaction of a number of risk factors. Once the protective 
layer of skin is broken, deep tissues are exposed to bacterial infection that progresses rapidly. Patients with 
DFUs frequently require amputations of the lower limbs and, in more than half the cases, infection is the 
preponderant factor. Given the challenges of treating these complex infections, this paper aims to provide a 
hospital-based framework for the diagnosis and treatment of diabetic foot infections (DFIs). We propose a 
treatment-oriented assessment of DFIs based on a cross-examination of the medical, foot, and wound history; 
a systemized and detailed physical examination; and the results of complementary diagnostic procedures. We 
stress the need for a clinical diagnosis of DFIs and the importance of microbiological evaluation for antibiotic 
therapy guidance. Regarding treatment, we propose a multidisciplinary approach prioritizing invasive infection 
drainage, necrosis debridement, and the prompt start of empirical antibiotic therapy, followed by complete 
and appropriate vascular reconstruction. For severe DFIs, we suggest that negative pressure wound therapy 
(NPWT) be included in the treatment pathway. We also provide rules for managing particular situations, such 
as osteomyelitis. It is our hope that this protocol will improve the hospital management of DFIs and, ultimately, 
the prognosis of DFI patients.
The world is facing a major epidemic of 
diabetes mellitus (DM). There are an estimated 
171 million diabetic patients worldwide and this 
number is expected to double by the year 2030 
1. All of these patients are at risk for developing a 
diabetic foot ulcer (DFU). A DFU is any full-thick-
ness wound below the ankle in a diabetic patient, 
irrespective of duration. Based on current 
studies, the annual population-based incidence 
is 1 to 4% with a prevalence of 4 to 10%, and the 
estimated lifetime risk is 25% 2. According to a 
study published by the Eurodiale study group 3, 
approximately 58% of DFU patients will become 
clinically infected. Patients with DM frequently 
require minor or major amputations of the lower 
limbs (15 to 27%) and in more than 50% of 
cases, infection is the preponderant factor 4. 
Major amputation is associated with significant 
morbidity and mortality (ranging from 13 to 40% 
at 1 year to 39 to 80% at 5 years 2) in addition 
to immense social, psychological, and financial 
consequences 5.
Introduction   
A prior DFU is an almost obligatory prereq-
uisite for DFIs. This is true even though, in some 
cases, the wound may have closed over before 
DFI presentation 9.Numerous observational 
studies have indicated that DFUs have a 
multifactorial nature. It is well established 
that insulin deficiency (absolute or relative) 
is the basis of the biochemical abnormali-
ties that lead to the organic complications 
of diabetes mellitus 12 (namely, neuropathy) 
and the biological deficits of tissue healing 
and regeneration. It has also been estab-
lished that perfect and persistent glycemic 
control, with either insulin or oral agents, 
stop 13 and probably regress 14 these com-
plications. DFUs result from a complex 
interaction of two major risk factors: neu-
ropathy and peripheral vascular disease. 
Neuropathy, both symmetric and bilateral, 
plays the main role with varying degrees 
of alterations in autonomic, sensory, and 
motor functions. Playing a secondary role is 
peripheral vascular disease resulting from 
atherosclerosis (Figure 1). Approximately 
50 to 60% of all DFUs can be classified as 
neuropathic. Signs or symptoms of vascular 
compromise are observed in 40 to 50% of 
all patients with the vast majority having neu-
roischemic ulcers, and only a minority of patients 
have purely ischemic ulcers 15.
Diabetic foot infection (DFI) treatment accounts 
for up to one-quarter of all diabetic admissions 
in both Europe and the United States making it 
the single most common reason for DM-related 
hospital admission 6. In the longer term, costs 
are even higher as DFUs have recurrence rates 
of up to 70% in centers of excellence, resulting 
in repeated interventions and progressive 
disability7. 
Recognizing this predictable progression, 
the solution includes developing structured 
screening tools to identify those at risk and 
implementing both standardized education and 
prevention protocols. Different countries and 
healthcare systems have implemented such 
approaches to diabetic foot care, some with 
reported success 4 and others with reported 
failure 8. As stated by Lavery et al. 9, however, 
even with the best of preventive care, 9% of 
patients with DM will still develop a DFI, with 
the consequent risk of amputation. This partial 
failure of prevention strategies supports the 
need to develop a framework for diagnos-
ing and treating patients with suspected DFIs. 
This assumes special importance in DFIs that 
require hospitalization, as strategies have proven 
efficacy in reducing morbidity, mortality, psycho-
logical distress, and financial costs10. Despite 
the publication of different clinical guidelines for 
DFI management, there is still practical variation 
in inpatient management 10,11. This paper aims 
to provide a hospital-based framework for the 
diagnosis and treatment of DFIs, based on a 
pathophysiological approach.
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Pathophysiology   
Figure 1: Diabetic foot ulcer (DFU) and diabetic foot infection (DFI) pathophysiology. 
DFU results from a complex interaction of a number of risk factors. Neuropathy (with 
alterations in motor, sensation, and autonomic functions) plays the central role and 
causes ulcerations due to trauma or excessive pressure in a deformed foot without 
protective sensibility. Once the protective layer of skin is broken, deep tissues are 
exposed to bacterial colonization. Infection is facilitated by DM-related immunological 
deficits, especially in terms of neutrophils, and rapidly progresses to the deep tissues.
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Neuropathy 
Diabetic peripheral neuropathy results from 
degenerative changes of axons and affects all 
nerve fibers, but at different times. The non-
myelinated autonomic nerve fibers are affected 
first, resulting in autosympathectomy with con-
sequent medial artery calcification (Mönckeberg 
calcification), microvascular thermoregulatory 
dysfunction, and arteriovenous shunting 16.  
Mönckeberg calcification, unlike atherosclerosis, 
does not reduce the arterial internal diameter. 
Noninvasive flow studies 17 have demonstrated a 
hyperperfusion of the foot, especially of the deep 
tissues, while transcutaneous oxygen pressure 
(TcPO2) measurements have shown a relative 
epidermal ischemia as a result of the microvas-
cular dysfunction and arteriovenous shunting 
18.  Autonomic neuropathy can cause anhidro-
sis leading to dry skin, cracking, and fissuring. 
This can create a portal of entry for bacteria 
19.  Contrary to the classical conceptualization, 
it is of the utmost importance to recognize that 
most diabetic persons have adequate circula-
tion necessary for a cure 17. In this time frame, in 
which autonomic dysfunction dominates, there is 
clinically a pathophysiologically resultant hot and 
turgid foot. Shortly after, other forms of neuropa-
thy become superimposed. Sensory neuropathy 
begins with poorly tolerated tactile allodynia and 
thermal hyperalgesia. As progressively thicker 
myelinated fibers are affected this progresses to 
an objective loss of sensation and propriocep-
tive dysfunction 20.  Motor neuropathy results 
from the axonal degeneration of the large motor 
myelinated fibers. This causes anterior crural 
muscle atrophy or intrinsic muscle wasting, 
which leads to foot deformities and consequent 
altered foot biomechanics with foot pressure 
redistribution 19. As the disease progresses, the 
foot becomes clinically insensitive and possibly 
deformed (claw toes, hammertoes, prominent 
metatarsal heads, etc.). 
Peripheral Arterial Disease (PAD) 
The first notion to consider is that vascular 
disease of the diabetic foot always results 
from tight and obliterative atherosclerosis in 
the large limb vessels and not from, as is most 
commonly believed, microvascular disease 21. 
This confusion results from the theoretical con-
clusion that diabetic multifactorial microvascular 
insufficiency applies to the foot; however, even 
the almost universal basal membrane thickening 
is not likely to be present in the foot capillaries 
22. DM is associated with a near 3-fold increased 
risk of accelerated atherosclerosis, which is 
histologically identical to that seen in the non-
diabetic population 23. This underlines the impor-
tance of identifying and aggressively managing 
associated vascular risk factors, such as obesity, 
cigarette smoking, dyslipidemia, hypertension, 
and sedentary behavior 24. The major difference 
in the diabetic population is the distribution of 
disease, which tends to be symmetrical with a 
more distal (tibio-peroneal) involvement and a 
predominance of long segment occlusions and 
calcification 25. When femoral disease is present, 
it tends to be diffuse with no single dominant 
focal lesion 23. 
Ulceration
Ulceration of the diabetic foot, either neu-
ropathic or ischemic, does not occur spontane-
ously. It usually follows some form of extrinsic 
or intrinsic trauma26. While extrinsic trauma may 
include any kind of thermal (e.g., scalding from 
hot water), chemical (e.g., abrasion from callus 
treatment solutions), or localized mechanical 
(e.g., puncture wounds from foreign objects) 
injuries, the most common injury leading to 
ulceration is continuous low-pressure trauma, 
typically from ill-fitting shoes, and injuries due to 
chronic repetitive trauma from walking or day-to-
day activity 27. Intrinsic traumas are also easily 
understood as they result from foot deformities 
(foot drop, equinus, hammertoes, and prominent 
plantar metatarsal heads) and consequent 
altered foot biomechanics 4. These foot  
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deformities result from the atrophy induced by 
motor neuropathy of the foot’s intrinsic muscles.
Infection
Once the protective layer of skin is broken, 
the deep tissues are exposed to bacterial coloni-
zation 28. Qualitative and quantitative aspects of 
wound microbiology are critical determinants of 
the wound outcome (Figure 2).
Staphylococcus aureus and ß-hemolytic 
streptococci are the first microorganisms to 
colonize and acutely infect breaks in the skin. 
Chronic wounds develop a more complex poly-
microbial microbiology, including aerobic Gram-
negative rods and anaerobes. Gram-negative 
bacilli, mainly Enterobacteriaceae, are found in 
many patients with chronic or previously treated 
infections, and Pseudomonas aeruginosa is 
specifically associated with wounds treated with 
wet dressings 29. Less virulent bacteria such as 
Enterococcus spp., coagulase-negative Staphy-
lococcus spp., or Corynebacterium spp. may 
also represent true pathogens 29. Anaerobes 
are rarely the sole pathogen, but they often 
participate in a mixed infection with aerobes, 
especially in cases of deep tissue infection 30. 
These mixed infections provide an optimal op-
portunity for microbial synergy, which increases 
the net pathogenic effect and hence the severity 
of infection 28. Accordingly, the composition of 
the polymicrobial wound flora is likely to be 
more important than the presence of specific 
pathogens. 
Assuming that the qualitative microbiol-
ogy remains constant, the probability of 
wound infection increases as the microbial 
load increases to a critical level. At this 
level, infection or a failure to heal is con-
sidered almost inevitable 28. In complex 
extremity wounds, this critical level has 
been established by Breidenbach et al. 31 
as a bacterial tissue count ≥104 CFU/g. 
There are exceptions to this rule of thumb, 
however, as various organisms have 
different intrinsic virulence potentials. A 
good example is ß-hemolytic streptococci 
which is able to induce tissue damage at 
102 CFU per gram of tissue, while greater 
counts of less pathogenic organisms may 
be of little clinical significance 32. A third 
critical factor is the efficacy of the host’s 
immune response in dealing with wound 
microflora.  In DFUs, infection is facilitated 
by intrinsic immunological deficits, espe-
cially in terms of neutrophil dysfunction. 33 
Notwithstanding, infection is also facilitated by 
local potentiating factors such as tissue necrosis, 
hypoxia (due to poor local perfusion accentu-
ated by the hypermetabolic state and microbial 
cellular metabolism), ischemia, and the particular 
anatomy of the foot (i.e., it is divided into several 
compartments, explaining the rapid spread of 
infection), all of which impair immune cell activity 
in the wound environment 10.
All of these complex interactions have been 
systematized by the wound infection continuum 
34. This concept describes the effects of increas-
ing bacteria quantity and diversity in 
Figure 2: Qualitative and quantitative aspects of diabetic foot infections (DFIs). 
Staphylococcus aureus and ß-hemolytic streptococci are the first microorganisms 
to colonize and acutely infect breaks in the skin. Chronic wounds develop a more 
complex polymicrobial microbiota, including aerobic Gram-negative rods and 
anaerobes.
Open access publishing The Journal of  Diabetic Foot Complications 2012;  Volume 4, Issue 2, No. 1, Pages 26-45
wound tissue, and their relationship to the quality 
of the host’s immune response. Simplistically, 
in relation to infection, the outcome of a wound 
may be depicted as the result of an equation: 
Acute and Chronic Wound Healing 
Physiology
In the acute wound setting, once the protective 
barrier is broken, the physiologic process of 
healing is immediately set in motion (Figure 3).
In this classic model 35 wound healing is divided 
into three sequential but overlapping phases: 
(1) the inflammatory phase, (2) the proliferative 
phase (re-epithelialization, granulation, and 
neo-angiogenesis), and (3) the remodeling 
phase (extracellular matrix remodeling). This 
complexly orchestrated biochemical cascade is 
characterized by signature events and cells, and 
their molecular regulators 36. In recent years, the 
scientific study of wound healing has progressed 
greatly making it impossible to summarize all the 
current knowledge in this article. Consequently, 
we will only describe the process of wound 
healing to the degree necessary for the clinician 
to apply this basic science to selecting treatment 
interventions and understanding their expected 
outcomes. 
The inflammatory phase starts with injury-
related subendothelial collagen-mediated platelet 
activation. Platelets degranulate, releasing 
proinflammatory and proliferative growth factors, 
including platelet-derived growth factor (PDGF), 
transforming growth factor-ß (TGF-ß), and basic 
fibroblast growth factor (bFGF). This initially 
results in vasoconstriction and the formation of a 
fibrin clot, which becomes the pathway 
for cellular influx and the primary foun-
dation for collagen deposition 37. Vaso-
constriction also promotes a hypoxic 
and acidotic wound space (secondary 
to anaerobic metabolism), which stimu-
lates vascular endothelial growth factor 
(VEGF) release and fibroblast infiltration 
38. In the second stage of the inflam-
matory phase, leukocytes attracted by 
chemotaxis, supplant platelets as the 
dominant cell type. Neutrophils are the 
first to begin bactericidal activities, using 
inflammatory mediators and oxygen 
free-radical metabolites. As these 
begin to wane, circulating monocytes, 
attracted by TGF-ß and PDGF, enter the 
wound and mature into tissue macro-
phages. These cells debride the wound 
on a microscopic level and produce 
cytokines necessary for the proliferative 
stage 36. 
The proliferation phase begins at 72 hours, 
as recruited fibroblasts migrate inward from the 
wound margins over the fibrin matrix established 
during the inflammatory phase. Initially stimulat-
ed by bFGF and PDGF, fibroblasts begin to syn-
thesize and deposit extracellular matrix (ECM) 
components (the provisional matrix). ECM is 
composed of fibrinous elements 
30
 
outcome = ( inoculum x virulence)+potentiating factors
host  resistance
 
Figure 3: Model of acute wound healing. Wound healing is divided into three sequential 
but overlapping phases: (1) the inflammatory phase, (2) the proliferative phase 
(re-epithelialization, granulation, and neoangiogenesis), and (3) the remodeling phase 
(extracellular matrix remodeling). This complexly orchestrated biochemical cascade is 
characterized by signature events and cells, and their molecular regulators.
(collagen, elastin and structural glycoproteins) 
and glycosaminoglycans (chondroitin sulfate, 
hyaluronic acid and dermatan sulfate), which 
attract large amounts of water and sodium 
collagen. Soon, fibroblasts become the dominant 
cell type and self-express TGF-ß – the negative 
regulator of acquired and adaptive immunity and 
the central regulator of tissue repair – directing 
collagen matrix formation and transforming 
into myofibroblasts, whose activities incite 
wound contraction and significantly reduce the 
area to be filled. This new microenvironment, 
with ECM-embedded fibroblasts coated with a 
layer of fibronectin, constitutes the scaffolding 
for the subsequent neo-angiogenesis and 
re-epithelization. Initially directed by fibroblasts 
that express keratinocyte growth factor-2 
(KGF-2) and interleukin-6 (IL-6), and later by 
nitric oxide (NO) and IL-6 self-expression, 
keratinocytes at the wound edges migrate 
laterally along the basal membrane and 
both proliferate and differentiate to produce 
the epidermis 36. In turn, keratinocytes direct 
neo-angiogenesis at the wound edge by 
expressing VEGF, which is upregulated by NO. 
The vasodilation induced by NO also aids in the 
movement of inflammatory cells to the site of 
injury. 
The final stage is the remodeling phase. 
This phase most clearly shows the overlapping 
of all woundhealing phases. Although classically 
described at the end of the proliferative phase, 
it actually begins concurrently with the formation 
of the granulation tissue and continues until the 
tissue reaches maturation. This phase involves 
a delicate equilibrium between tissue deposi-
tion and degradation, controlled by the activity 
of proteolytic enzymes – mainly matrix metallo-
proteinases (MMPs) – and their natural inhibitors 
– tissue inhibitors of metalloproteinase (TIMPs). 
Collagenase and other MMPs degrade Type III 
collagen, and Type I collagen fibrils are then laid 
down parallel to the wound lines of tension in an 
organized fashion, with strong cross-linking and 
bundle construction, replacing the lost tissue with 
an increased tensile strength 35.  
Chronic wounds are wounds that, following 
the orderly and timely repair process, fail to 
establish a sustained anatomic and functional 
result 39. The current thinking is that imbal-
ances exist in the molecular environment of 
these chronic nonhealing wounds. That is, 
when the scales are tipped towards high levels 
of MMPs and proinflammatory cytokines along 
with senescent cells, there is a low mitogenic 
activity that invariably results in chronicity 40. 
In diabetic wounds, a persistent inflammatory 
phase is commonly witnessed at histopathology, 
which is associated with a delay in the formation 
of mature granulation tissue and a reduction in 
wound tensile strength 41. Continuous bacterial 
infection 42 and increased advanced glycation 
end-product (AGE) formation 43 limit the cytokine 
(mainly TGF-ß)-mediated switch to the later 
granulation tissue formation phase. This results 
in prolonged inflammation and increased neutro-
phil infiltration with consequent protease activity.
Recognizing important risk factors and 
making a logical treatment-oriented assessment 
of DFIs requires a consistent and thorough di-
agnostic approach. Such an evaluation involves 
the careful assimilation of global medical, foot, 
and wound history; a systemized and detailed 
physical examination; and the results of comple-
mentary diagnostic procedures. Various systems 
have been proposed to classify DFUs, but none 
have gained widespread acceptance. The In-
ternational Working Group of the Diabetic Foot 
developed the PEDIS classification system 44,  
which presents internationally applicable guide-
lines that can reliably predict the outcome of 
diabetic foot management 45.
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The PEDIS system classifies all DFUs into 
subcategories of five main parameters 
(Perfusion, Extent/size, Depth/tissue loss, 
Infection and Sensation) according to strict 
criteria. Although it was not developed as a guide 
for daily management or to predict the outcome 
of an individual patient, it considers all the 
potentially useful information obtained from the 
clinical history, foot examination and diagnostic 
exams. Consequently, the use of this systematic 
examination ensures that important aspects are 
not overlooked.
Vascular Examination 
The vascular examination (“perfusion” in the 
PEDIS system) begins with the clinical evalua-
tion of intermittent claudication symptoms and 
the complementary palpation of dorsal pedal and 
posterior tibial pulses (Figure 4). 
Based on the present literature 25,44, the presence 
of both pulses in the foot, in combination with 
the absence of intermittent claudication, renders 
significant PAD unlikely. On the contrary, if one 
or two pulses are absent, clinically relevant PAD 
is more likely; however, pulses can be absent 
because of edema, making additional objective 
vascular assessment necessary to exclude PAD 
or to grade it if it is present 46.  In non-diabetic 
patients, measuring the systolic ankle blood 
pressure with a hand-held Doppler device and 
calculating the ankle/brachial index (by dividing 
the ankle pressure by the Doppler pressure 
measured in the brachial artery) is the next step 
25. An index <0.9 confirms a hemodynamically 
significant occlusive disease, and progressive 
decrements constitute a rough estimate of the 
severity of the occlusive disease in non-diabetic 
patients. Unfortunately, because of the arterial 
media calcification observed in up to one-third 
of diabetic patients, this technique has limited 
usefulness in this special population 47. On the 
other hand, more complex techniques, such as 
systolic toe-pressure measurement or TcPO2, 
were better predictors of healing in several 
studies 25. 
Although the PEDIS classifica-
tion system suggests the use of toe 
pressures or TcPO2 to exclude clini-
cally relevant vascular disease 44, the 
complexity and cost of its use precludes 
its generalized application outside of 
clinical studies. When used in clinical 
practice, the formal revascularization 
decision is based on information from 
previous clinical tests and duplex ultra-
sonography (B mode, color flow, and 
spectral Doppler analysis) 48. The ultra-
sonographic exam is a good, noninva-
sive method for delineating the periph-
eral arteries and enables the distinction 
of high-flow functional arteriopathy. If 
a possible revascularization is consid-
ered, intra-arterial digital subtraction 
angiography is conducted to properly 
visualize the arteries of the feet and 
evaluate the feasibility of revasculariza-
tion 49. Magnetic resonance (MR) angiography 
and computed tomography (CT) angiography, 
performed without direct arterial injection and
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Figure 4: Vascular examination. The presence of both pulses in the foot, in combination 
with the absence of intermittent claudication, renders significant PAD unlikely. If one 
or two pulses are absent, clinically relevant PAD is more likely. Establishing the ankle/
brachial index (by dividing the ankle pressure by the Doppler pressure measured in the 
brachial artery) is the next step, but the usefulness of this technique in diabetic patients 
is limited. Thus, in clinical practice, the formal revascularization decision is based on 
information from previous clinical tests and duplex ultrasonography (B mode, color flow 
and spectral Doppler analysis). The complexity and cost of toe pressure or TcpO2 use 
precludes their generalized application outside clinical studies. 
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without  iodinated contrast agent injection for 
MR angiography, can be alternatives to classic 
arteriography, especially for distal and calcified 
lesions.
Neurologic Examination 
To evaluate sensation (“sensation” in the 
PEDIS system), the Semmes-Weinstein 10-gram 
monofilament should be used. Loss of protec-
tive sensation in the affected foot is defined 
as absent light pressure sensation at two out 
of three sites on the plantar side of the foot 
(plantar aspect of hallux, first metatarsal, and 
fifth metatarsal), as described in the International 
Consensus on the Diabetic Foot 15. The properly 
calibrated 10-gram monofilament is an objective 
and simple instrument used to screen the 
diabetic foot for loss of protective sensation and 
has shown to be a significant and independent 
predictor of likely lower extremity amputations 
in the diabetic population 50. The PEDIS clas-
sification system considers the use of a 128-Hz 
tuning fork applied to the dorsum of the hallux 
at the base of the proximal phalanx to evaluate 
the presence or absence of vibration sensation. 
Although both tests have similar sensitivities 
for evaluating protective sensation loss, and 
combining modalities appears to increase speci-
ficity 51, we consider that, for practical purposes, 
the 128-Hz tuning fork should be reserved for 
clarifying equivocal results on the Semmes-
Weinstein 10-gram monofilament test in DFI 
cases. The cause and severity gradation of 
protective sensory loss are difficult to evaluate 
and do not provide clinically useful informa-




Wound evaluation (“extent/size” and “depth/
tissue loss items” in the PEDIS system) includes 
the evaluation of the size and depth of the 
wound, both of which should be determined 
after debridement. The size could be evaluated 
using a precise technique (planimetry or grid 
technique), however, this is not always possible 
in clinical practice. Instead, wound size and 
depth can be estimated by multiplying the largest 
diameter by the perpendicular largest diameter 
44. Ulcer depth should be evaluated related to 
the structures involved. Ulcers are divided into 
lesions confined to the skin, those penetrating to 
the subcutaneous structures (fascia, muscle, or 
tendon) and those involving subsequent layers of 
the foot (bone and/or joint).  
Infection 
The diagnosis of infection (“infection” in 
the PEDIS system) is clinical, based on the 
presence of symptoms and signs of inflamma-
tion 15, and must always be confirmed and clas-
sified according to the depth of involvement. In 
the PEDIS grading system, three parameters are 
particularly relevant to clinical management and 
outcome: the involvement of the skin only (Grade 
2), the involvement of deeper structures (Grade 
3), and the patient’s systemic inflammatory 
response (Grade 4). Further qualitative defini-
tions of clinical interest should also be consid-
ered: cellulitis (infection of the subdermis), nec-
rotizing cellulitis (infection-related tissue necrosis 
of the subdermis and dermis), necrotizing 
fasciitis (infection with involvement of the super-
ficial fascia, presenting as sloughing of the skin 
and a violaceous color of the integument, without 
pus or abscess), wet gangrene (infection associ-
ated with blackish necrotic tissues), and osteo-
myelitis (infection of the bone). To definitively 
categorize the patient into one of these groups 
different diagnostic procedures are indicated. 
All patients should have a complete blood count 
with differential, erythrocyte sedimentation rate 
(ESR), C-reactive protein (CRP) testing and, 
ideally, procalcitonin (PCT) testing. However, 
caution must be exercised when interpreting 
laboratory tests, as no marker is sufficiently 
sensitive and specific to confirm the diagnosis of 
DFI and tests are often misleading, even in the 
case of severe lesions 19. In these patients, the 
most sensible sign of infection is often recalci-
trant hyperglycemia despite regular
33
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anti-hyperglycemic regimens. In our 
clinical experience, CRP has proven 
to be a good test in the diagnosis and 
follow up of serious DFIs. The values 
of more specific inflammatory markers 
(i.e., combined CRP and procalcitonin) 
might also be of value in discriminating 
DFI and could help to ensure a more ra-
tional use of antibiotic agents 52. Recog-
nizing the insensibility of classical signs 
and laboratory tests for the diagnosis 
of DFI and that various factors suggest 
the presence of DFI in the absence of 
these classical signs 53, Lipsky et al. de-
veloped a DFI wound score that could 
also act as a reliable and useful tool for 
predicting clinical outcome 54.
Another problem is determining the 
presence of osteomyelitis (Figure 5). 
The International Working Group on the 
Diabetic Foot has proposed consensus 
criteria 55 for diagnosing diabetic foot 
osteomyelitis (Table 1) that remain to 
be validated in a properly designed 
trial. Clinical signs (pus in bone at 
surgery, detached bone in ulcer, visible 
cancellous/cortical bone, or chronic 
inflamed wound) and laboratory signs 
(elevated ECR) are highly variable, and 
some patients may have no signs that 
suggest underlying bone infection 56. A 
positive probe-to-bone test (i.e., when a 
sterile metal probe reveals a hard and 
gritty surface compatible with bone) in 
the presence of DFI appears to have 
a relatively variable positive predictive 
value, while a negative test in a low-risk 
patient markedly decreases the likeli-
hood of osteomyelitis 57. Plain radio-
graphs should be the initial imaging 
study, because in established cases, 
they often show characteristic patho-
logical findings (cortical erosion, peri-
osteal reaction, and mixed lucency and 
sclerosis). However, they are relatively 
insensitive, particularly in the first two 
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Figure 5:  Evaluation for the presence of osteomyelitis. The suspicion of osteomyelitis 
may arise from clinical or laboratory signs. The initial imaging studies should be plain 
radiographs, as they often show characteristic pathological findings in established cases. 
However, because they are relatively insensitive in the first two weeks, additional imaging 
studies may be necessary. Magnetic resonance (MR) imaging, which has a very high 
sensitivity for bone and deep soft-tissue infections, is preferred to nuclear medicine 
scans. The gold standard for diagnosing osteomyelitis remains histopathology of a 
positive culture from a properly obtained bone specimen.
Foot 
Osteomyelitis GRADE-0 GRADE-1
Definite Any 1 of the following:
    – positive bone culture and histology 
    – pus in bone at surgery
    – detached bone in ulcer 




1 probable + 2 
possible findings
Probable Any 1 of the following:
    – visible cancellous bone
    – MRI findings highly indicative of 
        osteomyelitis
    – positive bone culture or histology
2 possible findings
Possible Any 1 of the following:
    – cortex erosion on X-ray
    – MRI findings compatible with 
        osteomyelitis
    – positive probe-to-bone
    – visible cortical bone
    – ESR >70 mm/h
    – chronic inflamed wound
Unlikely Any 1 of the following:
    – normal MRI
    – normal bone scan
    – acute ulcer without inflammation
    – normal X-ray
Table 1 - International Working Group on the Diabetic Foot 
Consensus Criteria for Diagnosing Diabetic Foot Osteomyelitis
weeks after infection when no changes are 
frequently found. Furthermore, they are nonspe-
cific, because they do not permit the differential 
diagnosis of noninfectious neuro-osteoarthropa-
thy 58. 
To overcome this problem, many clinicians 
use technetium bone scans. These scans are 
more sensitive but rather nonspecific, espe-
cially in neuropathic patients 10. Combining bone 
scans with other scintigraphic techniques, such 
as white blood cell scans (Indium-111 leukocyte 
scans or other variations), improves specificity, 
although these tests are rarely used because 
they are expensive and time consuming 59. 
Studies 56 have shown that the best imaging test, 
when available, is MR imaging. MR imaging has 
a very high sensitivity for bone and deep soft-tis-
sue infections. Despite its high cost, this imaging 
test has gained wide acceptance in the manage-
ment of patients with DFI 60, as it can also be 
used for surgical planning. Newer techniques, 
such as positron emission tomography (PET) 
scans, appear promising, but their role is as 
yet undefined 61. The criterion gold standard for 
diagnosing osteomyelitis is a characteristic 
histopathology (acute or chronic inflam-
matory cells, or necrosis) associated with 
a positive culture from a properly obtained 
bone specimen ideally obtained at the time 
of surgical debridement or by fluoroscopic- 
or computed tomography-guided percu-
taneous biopsy 55. In comparison, culture 
results from associated soft tissue wounds 
or sinus tracts do not reliably correlate with 
those taken from bone 60.
In the absence of suspected osteomy-
elitis, bacteriological sampling, which must 
be done after mechanical debridement and 
cleansing of the wound with gauze soaked 
in sterile physiological saline, is indicated if 
a DFI ≥ Grade 2 is clinically confirmed. The 
best sampling technique remains a matter 
of debate. While tissue biopsy and fluid 
aspirate are considered the gold standard 
for diagnosing wound infection 28, such 
invasive tests are infrequently performed 
for superficial wounds or in many practice 
settings, such as outpatient clinics, due to 
concerns about enlarging the ulcer or inducing 
pain 28,62. Superficial swabbing of the wound is 
discouraged, but swabbing the base of the ulcer 
is acceptable if it is the only possible option 11. 
Independent of the sampling method, specimens 
must be placed in transport medium and be 
sent to the microbiology laboratory as quickly as 
possible. Assuming that there are no completely 
reliable microbiological methods to distinguish 
between pathogenic and nonpathogenic microor-
ganisms at the present time, microbiologists and 
clinicians must collaborate closely to interpret the 
results. They must also take into account the col-
lection conditions transport time, transport condi-
tions, and the type of bacteria isolated. These 
procedures are summarized in Figure 6.
Other Diagnostic Procedures
Other diagnostic procedures may be 
indicated in the assessment of DFIs. However, 
it should be noted that many of these tests lack 
the ability to provide a definitive diagnosis, and 
clinical correlation is always required.
Figure 6:  Choice of specimens to be performed as a function of the type of wound. 
Bacteriological sampling is indicated if a diabetic foot infection (DFI) corresponding 
to PEDIS Grades ≥2 has been clinically confirmed. Mechanical debridement and 
wound cleansing with gauze soaked in sterile physiological saline must precede 
sampling. Tissue biopsy and fluid aspirate are considered the gold standard for 
diagnosing wound infection, but deep swabbing of the wound is acceptable in special 
circumstances. Microbiologists and clinicians working in close collaboration must 
interpret the results, while taking into consideration the collection conditions, transport 
time, transport conditions, and the type of bacteria isolated. 35
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Although research continues to improve 
wound-healing modalities and show promising 
options for the future, the importance of pre-
vention cannot be overemphasized. The clini-
cally predictable progression from DFU to DFI, 
present in 85% of amputation cases 63, highlights 
the importance of implementing an integrated, 
standardized prevention and treatment protocol. 
In this disease-management program, preven-
tion strategies should be delivered by family 
physicians and diabetologists using structured 
screening tools at defined intervals, with high-risk 
patients referred to multidisciplinary foot care 
teams for treatment. Even when using these 
well-defined interfaces, less than 20% of patients 
are referred to specialized diabetic foot clinics 64. 
When a DFI patient presents to the care team, 
a multidisciplinary management strategy should 
be rapidly implemented (Figure 7). As previously 
described, evidence suggests that this reduces 
the incidence of major amputation. The multidis-
ciplinary team should include an endocrinologist/
diabetologist, a surgeon with relevant expertise 
in managing DFI, a tissue viability nurse, and, 
ideally, a podiatrist. These professionals should 
also have access to other specialist services 
such as those provided by vascular surgeons 
and orthopedists 11. 
When treating a DFI, the multidisciplinary 
team must consider the need for hospitaliza-
tion, prioritize the treatment and drainage of 
any invasive infection, and perform limited de-
bridement if necrosis is present. The assess-
ment of vascular supply adequacy as well as a 
complete and appropriate vascular reconstruc-
tion follows. Further treatment should be based 
on the severity of the infection. Superficial ulcers 
without residual ischemia can usually be treated 
on an outpatient basis with repeated debride-
ment, off-loading, and oral antibiotics. In other 
ulcers, formal debridement should be completed 
and, as accumulating evidence indicates, 
negative pressure wound therapy (NPWT) 
should be included in the treatment pathway 65.
Treatment 
36
Figure 7:  Management of diabetic foot infections (DFI). 
The multidisciplinary team must consider draining invasive 
infections, debriding necrosis, and promptly starting 
empirical antibiotic therapy, followed by complete and 
appropriate vascular reconstruction. Further treatment 
should be based on the severity of the infection. 
Superficial ulcers without residual ischemia can usually 
be treated on an outpatient basis. For other ulcers, a 
formal debridement should be conducted. Accumulating 
evidence also suggests that negative pressure wound 
therapy (NPWT) should be included in the treatment 
pathway. Assuming that debridement, infection, ischemia, 
offloading, and nutritional status are addressed, a wound 
that fails to improve within 2 to 4 weeks should prompt the 
clinician to consider alternative and adjunctive therapies. 
A biomechanically sound reconstruction, with or without 
amputation, should be part of the treatment plan to 
minimize the risk of recurrent ulceration.
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When used after adequate debridement in 
a well-vascularized bed, NPWT prepares the 
wound for closure by secondary intention or skin 
graft.  A wound that fails to improve within 2 to 
4 weeks should prompt the clinician to consider 
alternative and adjunctive therapies (assuming 
appropriate attention to debridement, infection, 
ischemia, offloading, and nutritional status). A 
biomechanically sound surgical reconstruction, 
with or without amputation, must be considered 
part of the treatment plan to minimize the risk of 
recurrent ulceration.
Need for Hospitalization
Hospitalization is the first decision to make 
regarding patients with a DFI, and determining 
its necessity requires considering many aspects. 
Patients with severe infection (Grade 4), deep 
wounds, suspected bone and joint involvement, 
and severe ischemia (gangrene) should be hos-
pitalized. They often may require surgical inter-
vention (debridement, drainage, bone resection, 
or possibly urgent revascularization), fluid resus-
citation, and metabolic derangement regulation 
through strict glycemic control (usually using 
insulin therapy). These are at least as important 
as selecting proper antibiotic therapy 10. Other 
factors suggesting the need for hospitaliza-
tion include metabolic instability (e.g., 
severe hypoglycemia or ketoacidosis), 
expected poor patient compliance, and 
the impossibility of outpatient care 10.
Infection Control: Empirical 
Antibiotic Therapy and Invasive 
Infection Drainage
Invasive infection drainage should 
be the first-line treatment for all ulcers, 
especially those associated with 
abscesses complicated by compart-
mental syndrome, extensive necrosis, 
or necrotizing cellulitis. Randomized 
clinical trials have shown that systemic 
antibiotics (including the most recently 
available agents) are of clinical value 
in DFI 10,66 and, as in the majority of 
infectious diseases, they must be provided as 
early as possible. However, as authoritative 
guidelines emphasize 10,11 and a recent system-
atic review confirms 67, no particular antimicrobial 
regimen has been shown to be superior to others 
in DFI treatment. The initial empirical antibiotic 
therapy in DFIs should aim to cover the most 
common pathogens and should be based on 
the known epidemiology of DFIs.  They should 
subsequently be refined according to initial 
response and elements of the patient assess-
ment 29. The severity of infection is essential in 
determining the appropriate antibiotic regimen 
10. Patients with mild infections who have not 
previously received antibiotic therapy usually 
have an infection caused by only one or two 
species of bacteria 68, and an antibiotic regimen 
should almost always include an agent active 
against Staphylococcus aureus and Streptococ-
cus spp. 29. Long-standing or severe DFIs need 
extended coverage to include commonly isolated 
Gram-negative bacilli, Enterococcus spp., and 
anaerobes. When culture and sensitivity results 
are available, these should be considered to 
select a narrower-spectrum antibiotic therapy 
and complete the course of therapy. However, 
some important considerations should be taken 
into account (Figure 8).
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Figure 8:  Empirical antibiotic regimen review. When culture and sensitivity results are 
available, these should be considered to select a narrower-spectrum antibiotic therapy 
and complete the course of therapy. If the lesion is healing and the patient is tolerating the 
empirical regimen, there may be no reason to change, even if some or all of the isolated 
organisms are resistant to the agents used. On the other hand, if the infection is not 
responding then the treatment should be changed to cover all of the isolated organisms. 
If the infection is worsening despite susceptibility of the isolated microorganisms, the 
fastidious organisms may have been missed on culture and a revised debridement should 
be conducted. 
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 If the lesion is healing and the patient is tolerat-
ing the empirical regimen, then there may be no 
reason to change, even if some or all of the iso-
lated organisms are resistant to the agents used. 
This is well illustrated by the Sidestep study 69, in 
which a favorable clinical response to ertapenem 
was noticed in patients in whom Enteroccus spp. 
and Pseudomonas aeruginosa were isolated de-
spite the ertapenem resistance of the latter iso-
lates. This may be due to either the disruption of 
microbial synergy or the differential importance 
of individual virulence potential. On the other 
hand, if the infection is not responding then treat-
ment should be changed to cover all the isolated 
organisms. If the infection is worsening despite 
the isolated microorganisms’ susceptibility, the 
possibility that fastidious organisms were missed 
on culture should be taken in account and a revi-
sion of debridement should be done.
Other factors that must be taken into account 
when selecting an antibiotic regimen are the 
route of administration (oral vs. antibiotics), the 
penetration of antibiotics into infected diabetic 
foot tissues, and the cost of treatment. The par-
enteral route should be used for severe infec-
tions, in the neuroischemic foot, when the agents 
used cannot be administered orally, or when the 
patient’s state is incompatible with oral therapy. 
In all other cases, outpatient oral therapy is 
recommended, provided that regular medical 
follow-up can be ensured. The optimal duration 
of antibiotic therapy has not been clearly estab-
lished, but it could be 1 to 2 weeks for simple 
forms and 2 to 4 weeks for moderate to severe 
forms of skin and soft tissue infections. Cost is 
also an important consideration, and antibiotic 
therapy should proceed as indicated by the 
clinical situation and severity of the infection, 
with the lowest cost. Understanding these basic 
principles behind choosing an antibiotic regimen 
is more important than knowing particular anti-
biotic regimens, and each hospital should have 
epidemiology-based antibiotic guidelines for DFI 
management. A final consideration is topical 
antimicrobial therapy. Although it’s not currently 
advisable for most clinically infected chronic 
wounds, it may have a role in specific circum-
stances 70. The application of any topical antibi-
otic should always be preceded by formal de-
bridement and may be considered for a properly 
managed wound with subclinical infection that 
is failing to heal or to help in the removal of 
biofilms, which have been implicated in persis-
tent infections 71. 
The presence of bone infection substantially 
alters the approach to therapy, but there are no 
validated or well-accepted guidelines for treating 
diabetic foot osteomyelitis 29,60. Classically, bone 
resection in chronic osteomyelitis was consid-
ered essential to a cure 60. This routine, however, 
has recently been disputed 72 because radical 
surgical solutions (such as transmetatarsal 
amputations) may result in altered biomechan-
ics, with a consequent higher risk of reulcer-
ation. Published nonrandomized case series 
on nonsurgical treatment with a prolonged (3 to 
6 months) course of antibiotics have reported 
clinical success in 65% to 80% of cases 10,73. 
While optimal therapy requires obtaining bone for 
culture, initial empirical therapy should virtually 
always cover Staphylococcus aureus, which 
causes most infections. The traditional recom-
mendations of initial parenteral therapy may be 
outdated by the introduction of newer agents 
with excellent oral bioavailability 29. Selected 
patients may benefit from implanted antibiotics 
(e.g., embedded in beads or cement), HBOT, or 
revascularization, whereas others may elect for 
long-term or intermittent antibiotic suppression 10. 
Revascularization
In the case of critical ischemia, once the 
infection has been controlled, revasculariza-
tion must be immediately considered. Ideally, 
revascularization should be done at the same 
time as the formal debridement procedure. In 
other cases, revascularization can be deferred 
and proposed secondarily, especially in cases 
of delayed healing. In these later cases, the 
criterion for revascularization should consider the 
patient’s status 
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performance, the potential for cicatrization, the 
site of the lesions, and the quality of the arte-
rial distal runoff. The current revascularization 
options for the DM patient include conventional 
open surgery and endovascular interventions, 
which are not mutually exclusive and are often 
combined. Open surgical techniques include 
endarterectomy for local lesions and peripheral 
bypass for long occlusions. For bypass surgery, 
a single segment of the greater saphenous vein 
is the best conduit, although acceptable results 
have been obtained with prosthetic grafts that 
do not cross the knee 74. Long-term results are 
good, with 5-year secondary patency rates >70% 
and limb salvage rates of 75 to 85% 75. Endovas-
cular options include angioplasty, with or without 
stenting, and atherectomy (i.e., atherectomy with 
excimer laser or a plaque excision device). This 
treatment modality has a number of advantages 
over bypass surgery, particularly its low morbidity 
and mortality rate. However, the restenosis rate 
is relatively high, especially in below-the-knee 
procedures for which it is as high as 50% over a 
5-year period 76. Since the main goal for patients 
with DFI is to obtain sufficient perfusion to con-
trol the infection and save the limb, this is signifi-
cant since this temporary improvement of perfu-
sion can be sufficient enough to promote healing 
and avoid amputation. However, it takes up to 28 
days after endovascular intervention for the new 
blood flow to have maximal effect at the wound’s 
edge, whereas this time frame is reduced to 4 
to 10 days after bypass surgery 77. The results 
of recent studies 78 indicate that endovascular 
therapy might take a prominent place in the 
treatment of PAD, especially in patients with 
significant comorbidities, and this applies even 
more to patients with DFI. Antiplatelet therapy 
should begin preoperatively and continue after 
an endovascular or surgical procedure 25.
Formal Drainage and Debridement
Drainage and debridement (surgical, me-
chanical, sharp, etc.) are two different but 
complementary surgical procedures. Drainage 
is the incision of an area of tissue phlegmon 
or abscess. This surgical procedure is particu-
larly important in deep infections of the plantar 
surface of the foot, where infection spreads 
through the tendon sheaths of the toe flexor 
muscles located in the compartment between the 
superficial fascia and the arch of the foot. This 
compartment serves as a non-expandable box, 
resulting in a compartment syndrome that leads 
to ischemia and tissue necrosis. Under these cir-
cumstances, the drainage must open the plantar 
fascia. Drainage of collected deep DFIs is 
urgent, in the authors’ opinion. The debridement 
process involves physically excising necrotic 
material and debris until normal tissue appears, 
thus enabling wound healing and removing a 
reservoir of potential pathogens 79. Mechani-
cal debridement, as elegantly demonstrated by 
Wolcott et al. 80, also opens a time-dependent 
antimicrobial therapeutic window. Members of 
the multidisciplinary team should be the only 
ones to perform debridement. They should 
implement the technique that best matches their 
specialist expertise and clinical experience, the 
patient’s preference, and the site of the ulcer 
11. Efforts should be made to only remove dead 
tissue, while preserving as much other viable 
tissue as possible. Sharp debridement with a 
scalpel, scissors, or tissue nippers is the conven-
tional procedure; however, to minimize damage 
to normal tissue, which sometimes occurs with 
normal surgical sharp debridement techniques, 
alternative debridement with a hydrosurgical 
water knife may be used 81. In all of the pro-
cedures, serial thin slices of tissue should be 
removed until normal tissue appears. 
The presence of clotted vessels, stringy 
fascia, or tendon indicates that the tissue is not 
viable and should be removed and shaved down 
to shiny hard tendon or fascia. Soft, grey bone 
is necrotic and should be resected to reveal 
clean, hard bone with punctuated bleeding at 
the surface. Odor is an excellent indicator of 
adequate debridement, and if the wound is 
odorless post-debridement the clinician can feel 
comfortable that the wound has been adequately 
debrided 64.
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Wet-to-dry dressings, hydrotherapy, biother-
apy, and other topical debriding agents provide 
alternative options to surgical debridement. Un-
fortunately, they are less definitive and controlla-
ble, require prolonged and repeated applications, 
and delay the application of other therapies 82. 
Debridement should be performed as soon as 
possible, bearing in mind that in neuroischemic 
ulcers, formal debridement other than drainage 
of infection should only be performed after or 
during revascularization procedures.
Negative Pressure Wound Therapy 
(NPWT)
NPWT includes a family of devices consist-
ing of specialized dressings, including adhesive 
drape and open-cell foam, cut to fill the wound 
defect and capable of transmitting constant 
or intermittent pressure throughout the wound 
using a feedback control mechanism. NPWT 
has proven its effectiveness in various diabetic 
foot wounds in several randomized, controlled 
studies 83-85; however, most of these studies have 
not addressed the preoperative infectious status, 
and few have addressed the use of NPWT in 
DFI. Be that as it may, recent physiopathological 
and clinical evidence justifies its use as a useful 
adjunct to the management of DFIs 65. 
Excessive physiopathological exudate in 
DFIs can be detrimental because it contains an 
imbalance of matrix metalloproteases (MMPs) 
and their inhibitors (TIMPs). NPWT increases 
the diffusion gradients, which facilitates the 
removal of excess interstitial fluid and infec-
tious materials and improves blood flow as well 
as consequent metabolic waste evacuation. 
Whether NPWT actually reduces the bacterial 
load is debatable, however, its clinical effec-
tiveness in DFIs has been demonstrated. The 
original animal study by Morykwas et al. 86 and 
the clinical study by Argenta et al. 87 showed 
that NPWT use resulted in enhanced granula-
tion tissue formation with improved bacterial 
clearance compared with control dressings. In 
other studies 88, NPWT reduced the bacterial 
count to 104 to 106 per gram of tissue within 4 to 
5 days. However, in a retrospective study, Weed 
et al. 89 showed that despite the clear beneficial 
effects of NPWT, bacterial colonization increased 
significantly within the range of 104 to 106 per 
gram of tissue during prolonged therapy. This 
was also evident in a study by Moues et al. 90, in 
which NPWT was compared with conventional 
moist dressing therapy and did not significantly 
decrease the total bacterial load. There were 
qualitative differences, however, with nonfermen-
tative Gram-negative bacilli showing a significant 
reduction and Staphylococcus aureus showing a 
significant increase. This suggests that bacterial 
burden reduction may occur within the first 4 to 
5 days, making subsequent therapy effective in 
decreasing wound size. This was also seen in 
the first large prospective and randomized study 
of NPWT use in the treatment of complex clean 
diabetic foot wounds 83. NPWT was effective 
(i.e., it showed a higher and faster healing rate 
with lower major amputation rates) at the cost of 
a higher but non-statistically significant infection 
rate. 
Several subsequent studies have demon-
strated NPWT’s effectiveness in DFIs, particular-
ly to treat osteomyelitis and soft tissue infections 
65,91-93, when used in conjunction with adequate 
debridement and appropriate antibiotics. A new 
strategy to amplify the bioburden control using 
a modified NPWT system with an infusion port 
to intermittently instill antimicrobial agents has 
been developed 94, but it has not been properly 
investigated in the clinical setting. In DFIs, there 
are no contraindications to NPWT, but special 
care should be taken to cover exposed blood 
vessels, prosthesis, or bone with natural tissues 
or several layers of fine-meshed, non-adherent 
synthetic material 64. Finally, but importantly, a 
number of studies 65,95,96 suggest that adding 
NPWT as part of a wound management strategy 
results in shortened hospital stays and a higher 
percentage of limb salvage, with consequent 
decreased overall medical costs. 
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Based on the presented evidence, we 
propose NPWT utilization as defined by Kim 
et al. 65. NPWT should be applied immediately 
after the revascularization procedure and formal 
debridement, while the patient is in the operating 
room. For the first 2 or 3 days, a continuous 
suction mode of 125 mmHg should be used 
and the dressing should be changed every 12 
to 24 hours, at which time the wound should 
be carefully evaluated for any residual necrotic 
material and subsequent debridement should be 
performed, if appropriate 64,97. Once the infection 
is controlled and the wound is stable, the suction 
mode should be changed to an intermittent cycle 
of 5 minutes on and 2 minutes off. The dressings 
should then be changed every 24 to 48 hours, as 
this has been shown to increase blood flow and 
improve granulation 86.
Off-loading and Non-NPWT Wound 
Dressings
No intervention is likely to be successful 
if the wound is not protected against external 
trauma; therefore, complete and permanent off-
loading of the wound must be ensured as strictly 
as possible. Many types of devices can off-load 
the infected wound, but it is important to choose 
one that permits easy inspection. In inpatients, 
either bed rest or wheelchair use (keeping the 
affected leg horizontal) is preferred 10,11. It is 
beyond the scope of this paper to analyze all 
available wound dressings. As there is insuf-
ficient evidence to recommend a specific wound 
dressing or any type of wound healing agent 
for DFIs, we agree with the National Institute of 
Health and Clinical Excellence (NICE) guide-
lines 11 that advise the multidisciplinary team to 
consider their clinical assessment of the wound, 
the patient’s preference, clinical circumstances, 
and acquisition cost. 
Reevaluation and Further Treatment
If infection or wound necrosis worsens (bad 
wound evolution) during NPWT, a review of 
debridement, infection, ischemia, and nutritional/
metabolic status should be performed. In this 
case, NPWT discontinuation should be con-
sidered. If the wound fails to improve despite 
repeated surgical interventions, alternative 
and adjunctive therapies should be considered 
(e.g., growth factors and hyperbaric oxygen 
therapy [HBOT]). According to a meta-analysis 
98, G-CSF treatment might reduce the duration 
of hospitalization, the risk of lower-limb am-
putation, and other infection-related invasive 
intervention, but it does not appear to have a 
significant effect on the duration of intravenous 
antibiotic treatment, the resolution of infection, or 
the rate of wound healing. Systemic HBOT has 
also been proposed, as infection and ischemia 
are considered the two main indications for this 
procedure. Its use was recently analyzed in a 
systematic review 99 of five RCTs in which it was 
associated with a reduction in major amputa-
tions, but not in minor amputations or time to 
heal. We agree with Lipsky et al. 10 that only 
additional randomized clinical trials can establish 
protocols for using these expensive and limited 
resources to treat DFIs. If these treatments fail 
or are not considered, amputation remains the 
only option in cases of severe infection, espe-
cially in the neuroischemic foot. The amputation 
level depends on the vascular status and should 
preserve heel weight-bearing with prosthesis. 
Major (leg or thigh) amputations should be ex-
ceptional, occurring only in cases of uncontrolled 
life-threatening infection. If healthy and well-vas-
cularized granulation tissue is observed (good 
evolution), depending upon the location and size 
of the wound, either a skin graft (for large skin 
defects on non-weight bearing surfaces) may 
be conducted, or secondary intention healing 
(for wounds on weight bearing surfaces) may be 
induced. A skin graft is an effective way to close 
a chronic ulcer, but it requires a healthy and well-
vascularized granulation bed to survive. To avoid 
infection while ensuring the adherence of the 
graft to the underlying bed and avoiding seroma 
or hematoma development, NPWT may still be 
necessary after grafting 100. After the wound has 
healed, a biomechanically sound foot recon-
struction must be completed in the presence of 
deformity to prevent the recurrence of foot ulcer-
ation.
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DM is a global epidemic and the diabetic 
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